SCHEMBL14005161

SCHEMBL14005161

CN(C)CCN(CCN(C)C)Cc1ccc(NNC(=O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.55
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
GAA P10253 5/20 0.47
ALDH1A1 P00352 4/20 0.46
LMNA P02545 3/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
AGTR1 P30556 1/20 0.46
HDAC1 Q13547 3/20 0.45
HDAC6 Q9UBN7 3/20 0.45
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC2 Q92769 1/20 0.44
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744997 0.76 ACHE (0.51) PTGS2BCHEACHEGAAALDH1A1
SCHEMBL4748582 0.74 PTGS2 (0.51) PTGS2GAAALDH1A1HDAC1HDAC6
SCHEMBL11520592 0.74 PTGS2 (0.68) PTGS2GAAALDH1A1LMNANPC1
SCHEMBL27611454 0.74 RORC (0.65) GAANPC1HDAC1HDAC6KDM4E
SCHEMBL14005302 0.73 PTGS2 (0.50) PTGS2GAAALDH1A1HDAC1HDAC6
SCHEMBL18157879 0.73 CALM1 (0.65) BCHEACHEALDH1A1LMNAKDM4E
SCHEMBL425101 0.73 PTGS2 (1.00) PTGS2GAAALDH1A1NPC1POLB
SCHEMBL6898441 0.72 PTGS2 (1.00) PTGS2GAAALDH1A1LMNANPC1
SCHEMBL12352712 0.72 BCHE (0.51) BCHEACHEALDH1A1NPC1AGTR1
SCHEMBL12222172 0.71 CALM1 (0.52) BCHEACHEALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293711-A1 Chemokine receptor modulators METASTATIX, INC. 2008-11-27 US disclosed
US-20080293711-A1 Chemokine receptor modulators METASTATIX, INC. 2008-11-27 US disclosed
WO-2008112156-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293711-A1 Chemokine receptor modulators CCR5, CCL2, CXCR4 PTGS2 604/4885BCHE 4575/4885ACHE 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.